Alliance Pharma's sales and profits for H1 2016 more than doubled following the acquisition of Sinclair Health Products last December. Revenue rose 104% to £46.4m, while pre-tax profit was up 113% to £11.7m. UK sales were £24m, compared to £18.3m in 2015, while sales in western Europe were £11.7m, up from 2015's £2.3m and sales outside of western Europe hit £10.7m, compared to £2.2m a year earlier. The company said it expects its full-year results will be "significantly higher" as it continues to expand into new markets including China, India and Brazil.
Alliance Pharma's sales and profits for H1 2016 more than doubled following the acquisition of Sinclair Health Products last December. Revenue rose 104% to £46.4m, while pre-tax profit was up 113% to £11.7m. UK sales were £24m, compared to £18.3m in 2015, while sales in western Europe were £11.7m, up from 2015's £2.3m and sales outside of western Europe hit £10.7m, compared to £2.2m a year earlier. One of Alliance's best-selling brands, scar reduction product Kelo-cote, is sold in 63 countries and brought in £4.1m in revenue.